More Substance Use News and Updates

A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).

A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).

Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.

Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.

Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.

In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.

Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.

Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...

Buprenorphine, whether administered sublingually or subcutaneously, appears to be an effective option for the treatment of opioid use disorder (OUD) with fentanyl use.